Addressing Unmet Needs in Medullary Thyroid Cancer

Rozita Yarmand, PhD
Published: Friday, May 31, 2019



Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses unmet needs in medullary thyroid cancer.

In medullary thyroid cancer, there is an activating missense mutation in the RET tyrosine kinase receptor, Yarmand says. As such, RET is active in the neuroendocrine tissue that normally expresses this protein. This suggests that RET is a prognostic indicator and an oncogene in medullary thyroid cancer.

The current standard of care for this disease includes multikinase TKIs like cabozantinib (Cabometyx) and vandetanib (Caprelsa). However, patients only have partial responses to these drugs and develop resistance rather quickly. Yarmand concludes there is a need for a novel compound with less toxicity and more durable responses than the currently available TKIs.
SELECTED
LANGUAGE


Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses unmet needs in medullary thyroid cancer.

In medullary thyroid cancer, there is an activating missense mutation in the RET tyrosine kinase receptor, Yarmand says. As such, RET is active in the neuroendocrine tissue that normally expresses this protein. This suggests that RET is a prognostic indicator and an oncogene in medullary thyroid cancer.

The current standard of care for this disease includes multikinase TKIs like cabozantinib (Cabometyx) and vandetanib (Caprelsa). However, patients only have partial responses to these drugs and develop resistance rather quickly. Yarmand concludes there is a need for a novel compound with less toxicity and more durable responses than the currently available TKIs.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x